Search results | infectives

Reports

Infectives Partnering Terms and Agreements

The Infectives Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the infectives/infection/infectious partnering deals and agreements entered into by the worlds leading healthcare companies

Hematology Partnering Terms and Agreements

The Hematology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the hematology partnering deals and agreements entered into by the worlds leading healthcare companies.

Bacterial Partnering Terms and Agreements

The Bacterial Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the bacterial partnering deals and agreements entered into by the worlds leading healthcare companies

Insights

Infectives vaccine partnering

A vaccine is a biological preparation that improves immunity to a particular disease

More merger talks for Claris Lifesciences: Pfizer, Amneal, Novartis…

India-based CLARIS Lifesciences Ltd., which operates a generic sterile injectables business, has become the belle of the ball as multi-national companies such as Pfizer Inc., Amneal, Novartis AG and Indian companies such as Lupin and Cipla, are lining up to play the

Top 50 pharma and biotech companies review – 2009 to 2014

The partnering and M&A  trends and deal analysis of the top 50 pharma and biotech companies reveals a flurry of data that is interesting to observe for efficient deal making.

Market research analysis: Monoclonal antibody partnering

A recent market research analysis of monoclonal antibody partnering has shown a high interest in partnering deals involving monoclonal antibody technology in the past few years

Diagnostics partnering: recent life science trends 2009-2014

Diagnostics are subject to numerous partnering deals every year. Here we provide a review of recent life science trends in deal making activity

Industry trends in vaccine dealmaking – 2009 to 2014

Industry trends suggest that vaccine research and development is an increasingly active component of healthcare business development. In recent years there has been a significant increase in vaccine partnering and M&A activity.

Industry trends in infectious vaccines dealmaking – 2009 to 2014

Industry trends suggest that infectious vaccines research and development is an increasingly active component of healthcare business development. The last decade has witnessed a significant number of infectious vaccines partnering and M&A activity

Antibiotics partnering analysis in biopharma industry

The  last two years alone has seen $1.9 billion spent on antibiotics partnering by the biopharma industry.

Antibody: recent life science partnering trends

Antibodies are the subject of numerous partnering deals every year, here we provide a review of recent partnering trends activity.

Forest

Forest Laboratories is a top pharmaceutical company based in New York, USA

Events

Sorry, your search returned no results.


Deals

Merck and Microbiotix in anti-infectives pharma partnering

Microbiotix in pharma partnering agreement with Merck, a big pharma company

AstraZeneca pharma partners with Broad Institute to advance infectives research

Big pharma, AstraZeneca and the Broad Institute in Cambridge, Massachusetts announced a pharma partners collaboration to identify new chemical compounds targeting bacterial and viral infections that could speed the development of new antibacterial and antiviral drugs

Galapagos and GlaxoSmithKline expand anti-infectives alliance

For this expansion, Galapagos receives a payment from GSK of EUR 2 million cash.

Pfizer enters into $17bn merger agreement with Hospira

Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars,

Merck acquires Cubist Pharmaceuticals for $9.5bn

Merck and Cubist Pharmaceuticals have entered into a definitive agreement under which Merck will acquire Cubist for $102 per share in cash, which represents a 35 percent premium to Cubist’s average stock price for the most recent five trading days.

ZAI Laboratory in $30 million Series A financing

ZAI Laboratory has raised more than $30 million in Series A financing from an international group of healthcare investors including Qiming, KPCB and Sequoia.

Collaboration agreement for developing gram-negative antibiotics

Euprotec has entered into an alliance with Cantab Anti-infectives as they seek to develop improved antibiotics to treat multidrug resistant Gram negative bacterial infections.

Adrelyx enters into pharma licensing agreement with Sanofi

Ardelyx has entered into pharma licensing with Sanofi for its novel phosphate transport NaP2b inhibitor program (also known as NaPi2b, Npt2b and SLC34A2) for $198 million.

Specialty Pharmaceuticals, Mylan, buys SEZ plant from Unichem for $26.27 million

Unichem Laboratories is selling its Indore-based SEZ plant to generic and specialty pharmaceuticals maker Mylan Laboratories for Rs 161 crore ($26.27 million), as per a stock market disclosure.

Janssen pharma partners with GSK acquiring GSK2336805

Janssen Pharmaceuticals pharma partners by announcing the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline